Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-31T14:57:58.768Z Has data issue: false hasContentIssue false
  • English
  • Français

Tratamiento de clozapina de un trastorno límite de la personalidad con comportamientos de automutilación graves

Published online by Cambridge University Press:  12 May 2020

Mélanie M. Ferrerri ,
Jean-Yves Loze ,
Frédéric Rouillon  and
Frédéric Limosin
Mélanie M. Ferrerri
Affiliation:
Servicio de Psiquiatría, Hospital Albert Chenevier, 40 rué de Mesly, 94010Créteil cedex, Francia
Jean-Yves Loze
Affiliation:
Servicio de Psiquiatría, Hospital Albert Chenevier, 40 rué de Mesly, 94010Créteil cedex, Francia
Frédéric Rouillon
Affiliation:
Servicio de Psiquiatría, Hospital Albert Chenevier, 40 rué de Mesly, 94010Créteil cedex, Francia
Frédéric Limosin
Affiliation:
Servicio de Psiquiatría, Hospital Albert Chenevier, 40 rué de Mesly, 94010Créteil cedex, Francia
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

ClozapinaTrastorno límite de la personalidadComportamientos de automodulaciónAnsiedad
Type
Caso clínico
Information
European Psychiatry (Ed. Española) , Volume 11 , Issue 6 , September 2004 , pp. 380 - 381
Copyright
Copyright © European Psychiatric Association 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Alvir, JMJ, Lieberman, JA, Safferman, AZ, Schwimmer, JL, Schaaf, JA. Clozapine-induced agranulocytosis. Incidente and risk factors in the United States. N Engl J Med 1993;329:162–7.Google ScholarPubMed
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA; 1994.Google Scholar
Barnard, L, Young, AH, Pearson, J, Geddes, J, O'Brien, G. A systematic review of the use of atypical antipsychotics in autism. J Psy-chopharmacol 2002;16:93–101.Google ScholarPubMed
Benedetti, F, Sforzini, L, Colombo, C, Maffei, C, Smeraldi, E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998;59:103–7.CrossRefGoogle ScholarPubMed
Chen, NC, Bedair, HS, McKay, B, Bowers, Jr MB, Mazure, C. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 2001;62:479–80.CrossRefGoogle Scholar
Chengappa, KN, Ebeiing, T, Kang, JS, Levine, J, Parepally, H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999;60:477–84.CrossRefGoogle ScholarPubMed
Frankenburg, FR, Zanarini, MC. Clozapine treatment of borderline patients: a preliminary study. Comprehensive Psychiatry 1993;34: 402–5.CrossRefGoogle ScholarPubMed
Sajatovic, M, Ramirez, LF, Kenny, JT, Mettzer, HY. The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients. Comprehensive Psychiatry 1994;35:29–33.CrossRefGoogle ScholarPubMed
Schotte, A, Janssen, PF, Megens, AA, Leysen, JE. Occupancy of central neurotransmitter receptors by risperidone, clozapine and halo-peridol, measured ex vivo by quantitative autoradiography. Brain Res 1993;631:191–202.CrossRefGoogle Scholar
Steinert, T, Schmidt-Michel, PÜ, Kaschka, WRConsiderable improvement in a case of obsessive-compulsive disorder in an emotionally unstable personality disorder, borderline type under treatment with clozapine. Pharmacopsychiat 1996;29:111–4.CrossRefGoogle Scholar